Literature DB >> 8600086

Sequelae in long-term survivors of small cell lung cancer.

A G Van Oosterhout1, P G Ganzevles, J T Wilmink, B W De Geus, R G Van Vonderen, A Twijnstra.   

Abstract

PURPOSE: Central nervous system (CNS) effects of chemotherapy and prophylactic cranial irradiation (PCI) are studied in long-term small cell lung cancer (SCLC) survivors. The exact significance and pathogenesis of the neurotoxicity is still unknown, as studies on this subject lack sufficient patient numbers and are performed in an extremely varied manner. METHODS AND MATERIALS: Fifty-nine survivors (> 2 years from diagnosis) were examined neurologically and neuropsychologically, and underwent a cranial computer tomography (CT) scan or magnetic resonance (MR). Eight patients were excluded from further analysis for various reasons (not SCLC-related CNS disease, n = 6; no chemotherapy nor PCI treatment, n = 2). The remaining 51 patients were divided into three groups; group 1 = chemotherapy alone (n = 21), group 2 = sequential PCI (n = 19), and group 3 = concurrent or sandwiched PCI (n = 11). Groups were neuropsychologically compared in matched controls.
RESULTS: Performance status did not differ significantly between various treatment groups; all patients remained ambulatory and capable of self-care. Mental impairment (n = 20), motor abnormalities (n = 9), and visual complaints (n = 1), were found in five patients in group 1 (24%), eight patients in group 2 (42%), and eight patients in group 3 (73%). Analysis of brain atrophy revealed no significant results; however, white matter abnormalities were found more frequently in group 3. Neuropsychologically no significant group differences existed, although interference sensitivity and difficulties with divided attention tended to occur more frequently in patients treated with PCI. Mean neuropsychometric results of treatment groups were significantly worse than those of matched controls.
CONCLUSIONS: Although more intensively treated patients showed more neurologic impairment and patients in group 3 had more white matter abnormalities, there was no statistic evidence for additional neurotoxicity of PCI. Marked neuropsychometric differences between patients and matched controls may indicate that cognitive impairment is partly disease related, probably due to emotional distress and deteriorated physical condition.

Entities:  

Mesh:

Year:  1996        PMID: 8600086     DOI: 10.1016/0360-3016(95)02257-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

Review 2.  Radiotherapy and radiosurgical management of brain metastases.

Authors:  J C Flickinger
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

3.  Tolerability and toxicity of prophylactic cranial irradiation in patients with non-small cell lung cancer - Results of a phase II study (with estimation of hematological toxicity, pituitary function and magnetic resonance spectra changes).

Authors:  Marzena Gawkowska-Suwińska; Sławomir Blamek; Alicja Heyda; Lukasz Boguszewicz; Anna Cichoń; Lukasz Zarudzki; Elżbieta Nowicka; Katarzyna Behrendt; Beata Smolska-Ciszewska; Grzegorz Plewicki; Aleksander Zajusz; Rafał Tarnawski
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-17

4.  Psychophysiological evaluation of short-term neurotoxicity after prophylactic brain irradiation in patients with small cell lung cancer: a study of event related potentials.

Authors:  C Parageorgiou; C Dardoufas; V Kouloulias; E Ventouras; N Uzunoglu; L Vlahos; A Rambavilas; G Christodoulou
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

5.  Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).

Authors:  C Le Péchoux; A Laplanche; C Faivre-Finn; T Ciuleanu; R Wanders; D Lerouge; R Keus; M Hatton; G M Videtic; S Senan; A Wolfson; R Jones; R Arriagada; E Quoix; A Dunant
Journal:  Ann Oncol       Date:  2010-12-07       Impact factor: 32.976

6.  Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function.

Authors:  S B Schagen; H L Hamburger; M J Muller; W Boogerd; F S van Dam
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

7.  Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer.

Authors:  Aaron H Wolfson; Kyounghwa Bae; Ritsuko Komaki; Christina Meyers; Benjamin Movsas; Cecile Le Pechoux; Maria Werner-Wasik; Gregory M M Videtic; Yolanda I Garces; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

8.  Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors.

Authors:  Grit Welzel; Katharina Fleckenstein; Sabine K Mai; Brigitte Hermann; Uta Kraus-Tiefenbacher; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

9.  Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors.

Authors:  Stephanie A Reid-Arndt; Albert Yee; Michael C Perry; Catherine Hsieh
Journal:  J Psychosoc Oncol       Date:  2009

10.  Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer.

Authors:  Stephanie A Reid-Arndt; Catherine Hsieh; Michael C Perry
Journal:  Psychooncology       Date:  2010-05       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.